Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 39.31B P/E 12.96 EPS this Y 9.60% Ern Qtrly Grth -1.40%
Income 1.16B Forward P/E 16.14 EPS next Y 6.00% 50D Avg Chg -6.00%
Sales 9.67B PEG 3.28 EPS past 5Y -16.74% 200D Avg Chg -5.00%
Dividend N/A Price/Book 2.72 EPS next 5Y 3.60% 52W High Chg -15.00%
Recommedations 2.10 Quick Ratio 1.28 Shares Outstanding 145.66M 52W Low Chg 40.00%
Insider Own 0.17% ROA 5.19% Shares Float 145.13M Beta -0.06
Inst Own 92.70% ROE 7.63% Shares Shorted/Prior 3.67M/2.68M Price 271.56
Gross Margin 76.45% Profit Margin 11.98% Avg. Volume 1,141,158 Target Price 268.33
Oper. Margin 32.50% Earnings Date Nov 6 Volume 1,291,128 Change 0.84%
About Biogen Inc.

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Biogen Inc. News
11/20/24 Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside
11/19/24 Biogen Inc. (BIIB): Among the Best Genomics Stocks to Buy Right Now
11/19/24 Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
11/18/24 Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026
11/18/24 Needham downgrades Biogen on slow growth of Alzheimer's drug
11/18/24 Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
11/18/24 Is Biogen Inc. (BIIB) A Cheap NASDAQ Stock To Invest In Now?
11/15/24 Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
11/14/24 European committee takes a second look at Alzheimer's drug and now says it should be approved
11/14/24 5 Healthcare Stocks to Buy in a Beaten-Up Sector
11/14/24 Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease
11/14/24 Is Eli Lilly Stock A Sell After Its Disastrous Third-Quarter Report?
11/14/24 Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
11/14/24 Citi initiates coverage on 5 new biotech stocks
11/14/24 RNA Stock Hits Record High on Entering the Cardiac Disease Space
11/13/24 Novavax Q3 Earnings & Sales Beat, Stock Falls 6% on '24 View Cut
11/12/24 Repligen Beats on Q3 Earnings & Sales, Narrows '24 Sales View
11/12/24 Here's Why Biogen Inc. (BIIB) is a Strong Value Stock
11/06/24 Perrigo's Q3 Earnings Fall Short of Estimates, Sales View Updated
BIIB Chatroom

User Image STOCKSBOOTCAMP Posted - 51 minutes from now

Mr. Justin Bieber coming out swinging $BIIB lol

User Image NexitAdvisors Posted - 49 minutes from now

⬆️ $BIIB STRONG BUY✅ TP-> 223$

User Image Jjjsn33dfulthings Posted - 34 minutes from now

$BIIB come on. Rotate out of tech into my baby here. I've been waiting. Come to papa $JNJ $QQQ $SPY

User Image SparkyReturns Posted - 5 minutes from now

$MCK Hey, anyone looking for an investing idea in the biotech space would do well to check out ICU - SeaStar Medical. Last quarter was the first time they started to book revenue from their SCD device which is unique and has received FDA grants and also multiple Breakthrough Device Designations. They just took over direct sales from a prior distributor, and revenue is ramping up rapidly. Eventually every hospital ICU in the country will have to buy these as it becomes new standard of care for treating sepsis and CKD. They have NO competition. It is at the inflection point and could bounce hard from the current bottom forming. Likely blockbuster at the gate. Cheers! $AMGN $BIIB $SNY

User Image doctordinero Posted - 7 minutes ago

$BIIB Added more call LEAPS GLTA $SPY $IBB

User Image erevnon Posted - 21 minutes ago

Mizuho maintains Biogen $BIIB at Outperform and lowers the price target from $251 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Jjjsn33dfulthings Posted - 44 minutes ago

@markwyatt ya, it is, I completely forgot about it. Worst case I pay the tax and give the account to my son as a Christmas present lol. If I wasn't married it would be way easier ha No I'm stressing out in all honestly. Hope everyone has a great trading day. I gotta go fig this out $POWL $U and I'm still waiting on $BIIB I will wait to see what it looks like at 345 and see what's moved and what hasn't today. Toodles

User Image PencilNeckGeek Posted - 1 hour ago

$BIIB this looks good for a swing. RSI below 20

User Image TheMarketMaster Posted - 12 hours ago

$BIIB just entered today! Now let’s 🚀

User Image Market_Max Posted - 16 hours ago

$SAVA So two high-profile folks joined Cassava Sciences this week. We have a Chief Commercial officer and a chief clinical development officer (with solid credentials in Neuroscience btw) and over 21yrs of experience with Pfizer and last 7yrs with $BIIB So all the doubters and naysayers ( Adam Fraudstain, Martin Shkirelli, Adrian, Elizabeth Bik, Jesse Broken, etc etc) think the company embarks on these high-profile hiring (particularly the announcements at this moment) without any incline as to whether there's a Yay or Nay Simufilam works for Alzheimer's ? Think again!

User Image Stocksrunner Posted - 18 hours ago

Unusual options activity is heating up today! 🔥 Keep an eye on $BIIB $CORZ $DAL $DKNG and $MSFT — big moves might be on the horizon! https://stocksrunner.com/posts/1403

User Image Jjjsn33dfulthings Posted - 19 hours ago

$BIIB suck it bears. We own you. Haha shorty. You broke. Yadda yadda. Odds on tomorrow. If it finishes green then I'm sure there will be profit taking so it'll pause tomorrow haha

User Image Jjjsn33dfulthings Posted - 19 hours ago

$BIIB holy crap. R we gonna end the day green. Someone check me please. I think I'm having a stroke

User Image Article_AI Posted - 20 hours ago

$BIIB Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside On Tuesday, UCB SA UCBJY UCBJF and Biogen Inc. BIIB presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus. https://www.stck.pro/news/BIIB/93699769/

User Image mickeyp_ Posted - 22 hours ago

$BIIB Co-pilot is the best Biogen's forward PE ratio of 10.29 is indeed one of the lowest it's been in recent years. Over the past decade, Biogen's PE ratio has typically ranged from 12 to 32, with the lowest being 7.83 in June 2020 (COVID) and the highest reaching 32.27 in December 2023.

User Image InvestingWithoutPain Posted - 22 hours ago

$BIIB 666 $152.50 strike put option volume today. Tell me this isn’t being manipulated???

User Image mickeyp_ Posted - 22 hours ago

$BIIB fun fact this is trading at 2013 prices and in 2013 they had roughly 100 million more shares... 2010: 255 million shares 2015: 231 million shares 2020: 161 million shares 2024: 146 million shares

User Image mickeyp_ Posted - 22 hours ago

$BIIB analysts have the best job in the world !!! what are analysts price predictions for biogen Analysts have varying price predictions for Biogen (BIIB) over the next 12 months. Here are some key insights: Average Price Target: Around $258.96 to $260.481. High Estimate: Approximately $342.001. Low Estimate: Around $180.001. Consensus Rating: Generally, analysts rate Biogen as a "Buy" or "Moderate Buy".

User Image mickeyp_ Posted - 22 hours ago

$BIIB so this is trading at 2013 prices WELL DONE MANAGEMENT !!!! GIVE YOURSELVES A BIG FAT BONUS

User Image BenicioMontgomery Posted - 1 day ago

$ALNY $BIIB LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?

User Image Jjjsn33dfulthings Posted - 1 day ago

$BIIB ok let's flip the coin Heads it will be down Tails it won't be up Ok you pick

User Image look2theblue Posted - 1 day ago

$BLUE A $2 price target seems reasonable, because that's about where they will end up forcing a fire sale next month. I think either $BIIB or $PFE picks them up. This will never see above $2.

User Image Antwan61186 Posted - 1 day ago

$BIIB who’s ready for 🚀

User Image InvestingWithoutPain Posted - 1 day ago

$BIIB

User Image MF__DOOM Posted - 1 day ago

$BIIB $BMY $LLY $MRNA $REGN

User Image Jjjsn33dfulthings Posted - 1 day ago

$UVXY love the days where this and $SPY are both up. Been playing $U almost all day. Going to hold that position for a bit. Added to $BIIB. Will continue to add at every 5 down and just hold onto.

User Image momobull Posted - 1 day ago

$BMY no kill by RFK? He can only kill these $REGN $LLY $BIIB $MRNA ok, everything makes sense.

User Image hopefulkk Posted - 1 day ago

$BIIB 😞 never seen a stock have these many consecutive red days… what kind of management will allow them to do that

User Image creolej Posted - 1 day ago

$BIIB trying to find the bottom. It's unbelievable to be this low.

User Image Gksjr Posted - 1 day ago

$BIIB i have no clue what's going on here.. wiped out all my gains for the year across my portfolio

Analyst Ratings
Needham Buy Sep 24, 24
Wedbush Neutral Sep 23, 24
RBC Capital Outperform Sep 19, 24
Cantor Fitzgerald Overweight Sep 9, 24
Needham Buy Sep 4, 24
Needham Buy Aug 19, 24
Mizuho Outperform Aug 6, 24
Truist Securities Buy Aug 5, 24
Needham Buy Aug 5, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Singhal Priya Head of Development Head of Development Feb 01 Sell 245.93 634 155,920 4,097 02/05/24
Singhal Priya Head of Development Head of Development Feb 01 Option 0 1,828 5,292 02/05/24
Singhal Priya Head of Development Head of Development Dec 08 Sell 248 110 27,280 3,464 12/12/23
Singhal Priya Head of Development Head of Development Dec 08 Option 0 426 3,780 12/12/23
Singhal Priya Head of Development Head of Development Sep 01 Sell 269.43 431 116,124 3,354 09/06/23
Singhal Priya Head of Development Head of Development Sep 01 Option 0 1,668 4,592 09/06/23
Gregory Ginger EVP, Human Resources EVP, Human Resources Apr 28 Sell 300.00 2,681 804,300 8,483 05/02/23
Singhal Priya Head of Development Head of Development Apr 04 Sell 277.11 91 25,217 2,843 04/06/23
Singhal Priya Head of Development Head of Development Mar 28 Sell 270.06 568 153,394 2,842 03/30/23
Gregory Ginger EVP, Human Resources EVP, Human Resources Nov 14 Sell 300.11 5,610 1,683,617 5,711 12/12/22
ALEXANDER SUSAN H EVP Chief Legal Off.. EVP Chief Legal Off & Corp Sec Oct 27 Sell 280.70 5,532 1,552,832 39,396 10/28/22